Objective—To identify a causative mutation for dilated cardiomyopathy (DCM) in Doberman Pinschers by sequencing the coding regions of 10 cardiac genes known to be associated with familial DCM in humans.
Animals—5 Doberman Pinschers with DCM and congestive heart failure and 5 control mixed-breed dogs that were euthanized or died.
Procedures—RNA was extracted from frozen ventricular myocardial samples from each dog, and first-strand cDNA was synthesized via reverse transcription, followed by PCR amplification with gene-specific primers. Ten cardiac genes were analyzed: cardiac actin, α-actinin, α-tropomyosin, β-myosin heavy chain, metavinculin, muscle LIM protein, myosinbinding protein C, tafazzin, titin-cap (telethonin), and troponin T. Sequences for DCM-affected and control dogs and the published canine genome were compared.
Results—None of the coding sequences yielded a common causative mutation among all Doberman Pinscher samples. However, 3 variants were identified in the α-actinin gene in the DCM-affected Doberman Pinschers. One of these variants, identified in 2 of the 5 Doberman Pinschers, resulted in an amino acid change in the rod-forming triple coiled-coil domain.
Conclusions and Clinical Relevance—Mutations in the coding regions of several genes associated with DCM in humans did not appear to consistently account for DCM in Doberman Pinschers. However, an α-actinin variant was detected in some Doberman Pinschers that may contribute to the development of DCM given its potential effect on the structure of this protein. Investigation of additional candidate gene coding and noncoding regions and further evaluation of the role of α-actinin in development of DCM in Doberman Pinschers are warranted.
Objective—To evaluate the potential importance of
dystrophin, α-sarcoglycan (adhalin), and β-dystroglycan,
by use of western blot analysis, in several breeds
of dogs with dilated cardiomyopathy.
Sample Population—Myocardial samples obtained
from 12 dogs were evaluated, including tissues from
7 dogs affected with dilated cardiomyopathy, 4 control
dogs with no identifiable heart disease (positive control),
and 1 dog affected with Duchenne muscular dystrophy
(negative control for dystrophin). Of the affected
dogs, 4 breeds were represented (Doberman
Pinscher, Dalmatian, Bullmastiff, and Irish
Procedure—Western blot analysis was used for evaluation
of myocardial samples obtained from dogs
with and without dilated cardiomyopathy for the presence
of dystrophin and 2 of its associated glycoproteins,
α-sarcoglycan and β-dystroglycan.
Results—Detectable differences were not identified
between dogs with and without myocardial disease in
any of the proteins evaluated.
Conclusions and Clinical Relevance—Abnormalities
in dystrophin, α-sarcoglycan, and β-dystroglycan proteins
were not associated with the development of
dilated cardiomyopathy in the dogs evaluated in this
study. In humans, the development of molecular biological
techniques has allowed for the identification of
specific causes of dilated cardiomyopathy that were
once considered to be idiopathic. The use of similar
techniques in veterinary medicine may aid in the identification
of the cause of idiopathic dilated cardiomyopathy
in dogs, and may offer new avenues for therapeutic
intervention. ( Am J Vet Res 2001;62:67–71)